Preventing atherosclerotic cardiovascular disease in adults will require innovative public health approaches focused on children and families, to improve risk factor trajectories across the lifespan and prioritize children at highest risk of future disease.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Holman, R. L., McGill, H. C. Jr, Strong, J. P. & Geer, J. C. Am. J. Pathol. 34, 209–235 (1958).
McGill, H. C. Jr, McMahan, C. A., Malcom, G. T., Oalmann, M. C. & Strong, J. P. Arterioscler. Thromb. Vasc. Biol. 17, 95–106 (1997).
McNamara, J. J., Molot, M. A., Stremple, J. F. & Cutting, R. T. JAMA 216, 1185–1187 (1971).
Li, S. et al. JAMA 290, 2271–2276 (2003).
Jacobs, D. R. Jr et al. N. Engl. J. Med. 386, 1877–1888 (2022).
Navar-Boggan, A. M. et al. Circulation 131, 451–458 (2015).
Zhang, Y. et al. JAMA Cardiol. 6, 1406–1413 (2021).
Di Cesare, M. et al. BMC Med. 17, 212 (2019).
Buttermore, E., Campanella, V. & Priefer, R. Diabetes Metab. Syndr. 15, 102253 (2021).
Song, P. et al. JAMA Pediatr. 173, 1154–1163 (2019).
Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents & National Heart, Lung, and Blood Institute. Pediatrics 128, S213–S256 (2011).
de Ferranti, S. D. et al. J. Pediatr. 185, 99–105.e2 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.A.d.L. has received personal fees for participating in steering or data safety monitoring committees from Amgen, Regeneron, Verve Therapeutics, Novo Nordisc, Eli Lilly and Astra Zeneca. A.M.N. has received funding for research to her institution from BMS, Esperion, Amgen, and Janssen, and personal fees from Amarin, Amgen, Astra Zeneca, BI, Bayer, CSL, Esperion, Janssen, Lilly, Sanofi, Regeneron, NovoNordisk, Novartis, New Amsterdam, and Pfizer.
Rights and permissions
About this article
Cite this article
de Lemos, J.A., Navar, A.M. A life-course approach to cardiovascular disease prevention. Nat Med 28, 1133–1134 (2022). https://doi.org/10.1038/s41591-022-01870-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-022-01870-8
